XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
B
B

BayerAG


Actualités

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead May 10 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 14-May-2024 NTS PSHG_p.DE Porsche Automobil Holding SE Q1 2024 Porsche Automobil Holding SE Earnings Release 14-May-2024 BMO HNRGn.DE Hannover Rueck SE Q1 2024 Hannover Rueck SE Earnings Release 14-May-2024 BMO BNRGn.DE Brenntag SE Q1 2024 Brenntag SE Earnings Release 14-May-2024 05:30 RHMG.DE Rhein
B
B
C
D
E
H
P
R
R
S
A
G

War upends Ukraine's economy in a shift that may be permanent

ANALYSIS-War upends Ukraine's economy in a shift that may be permanent Russia's invasion causes huge upheaval for Ukraine's economy Thousands of companies move from east to west Heavy industries decimated, other sectors manage to adapt Firms' mass migration across Ukraine creates opportunities Much could yet change depending on the course of the war By Olena Harmash KYIV, May 9 (Reuters) - Within days of Russian forces invading Ukraine in early 2022, architect Oleh Drozdov made up his mind: he w
B

Singtel-owned Optus taps Rue as CEO to restore strategy and trust

UPDATE 3-Singtel-owned Optus taps Rue as CEO to restore strategy and trust Stephen Rue running Australia's NBN since 2018 Singtel shares up as much as 1.3% Rue has sound financial expertise in running Australian businesses - analyst Rewrites throughout, updates with shares, more details and background, new analyst comment By Rajasik Mukherjee and Rishav Chatterjee May 6 (Reuters) - Singapore Telecommunications-owned STEL.SI Optus said on Monday it had appointed Stephen Rue to lead the Australian
B
N

Regeneron's blockbuster eye drug posts weaker sales due to inventory impact

UPDATE 3-Regeneron's blockbuster eye drug posts weaker sales due to inventory impact Adds details on Eylea sales miss in paragraph 2, consensus estimates for Eylea 8mg in paragraph 5 May 2 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc REGN.O missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory.
B
R
S

European shares ease after Fed decision, mixed earnings

UPDATE 2-European shares ease after Fed decision, mixed earnings For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. ING jumps on new share buyback, strong Q1 Novo Nordisk slides as obesity drug concerns weigh Hugo Boss shares fall on weaker China demand, US uncertainty EZ factory activity took turn for the worse in April- PMI STOXX down 0.2% Updated at 1600 GMT By Ankika Biswas and Johann M Cherian May 2 (Reuters) - European shares fell sl
B
H
I
S
T
E
F
U
G

Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court

UPDATE 1-Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court Updates MAY 1 story to add Bayer background and shares in paragraphs 5-6, Bayer comments in paragraphs 10-11 By Clark Mindock May 1 (Reuters) - A Washington state appeals court overturned on Wednesday a $185 million verdict against Bayer's BAYGn.DE Monsanto unit over chemical contamination at a Seattle-area school, marking the second big legal win for the company in as many weeks.
B
P

Bayer shares rise as Monsanto wins US appeal over PCB case

BUZZ-Bayer shares rise as Monsanto wins US appeal over PCB case ** Shares in Bayer BAYGn.DE rise 4.8% after its Monsanto unit won an appeal over a $185 million verdict related to now-banned chemicals called polychlorinated biphenyls (PCBs) ** A Washington state appeals court overturned the verdict in a case over chemical contamination at Sky Valley
B
P

Europe eyes muted start post-Fed

LIVE MARKETS-Europe eyes muted start post-Fed Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE EYES MUTED START POST-FED Shares in Europe were set to open without clear direction on Thursday as traders returned to their desks after the Labour day holiday and following few surprises from the U.S.
A
B
H
I
I
F
U
G

Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court

Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court By Clark Mindock May 1(Reuters) - A Washington state appeals court on Wednesday overturned a $185 million verdict against Bayer's BAYGn.DE Monsanto unit over chemical contamination at a Seattle-area school, marking the second big legal win for the company in as many weeks.
B
P

Bayer must face US company's flea and tick drug antitrust lawsuit

Bayer must face US company's flea and tick drug antitrust lawsuit By Mike Scarcella May 1 (Reuters) - Life-sciences giant Bayer BAYGn.DE must face a U.S. antitrust lawsuit accusing a former unit of the German company of undermining competition for rival tick and flea treatments, according to a ruling unsealed on Wednesday. U.S. District Judge Beth Freeman in San Jose, California, said the plaintiff, pet products company Tevra, provided sufficient evidence for a jury to hear claims that Bayer sch
B

Bayer Expands Partnership With Huma Digital Heart Risk Assessment Tool Expands To Saudi Arabia

BRIEF-Bayer Expands Partnership With Huma Digital Heart Risk Assessment Tool Expands To Saudi Arabia May 1 (Reuters) - Bayer AG BAYGn.DE : BAYER EXPANDS PARTNERSHIP WITH HUMA: DIGITAL HEART RISK ASSESSMENT TOOL EXPANDS TO SAUDI ARABIA Source text for Eikon: ID:nPn2wTZnpa Further company coverage: [BAYGn.DE] ( Reuters.Briefs@thomsonreuters.com )
B

Bayer And Evotec Collaborate To Advance Precision Cardiology

BRIEF-Bayer And Evotec Collaborate To Advance Precision Cardiology April 30 (Reuters) - Evotec Se EVTG.DE : BAYER AND EVOTEC COLLABORATE TO ADVANCE PRECISION CARDIOLOGY EVOTEC: STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS BAYER AND EVOTEC WILL SHARE RESPONSIBILITIES DURING PRE-CLINICAL DEVELOPMENT OF POTENTIAL CLINICAL CANDIDATES BAYER WILL BE RESPONSIBLE FOR ANY SUBSEQUENT CLINICAL DEVELOPMENT AND COMMERCIALISATION.
B

J&J, Bristol Myers lose challenges to US drug price negotiation program

J&J, Bristol Myers lose challenges to US drug price negotiation program By Brendan Pierson April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb BMY.N and Johnson & Johnson JNJ.N to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.
A
B
P

The Agnellis’ risky Philips bet starts to pay off

CORRECTED-BREAKINGVIEWS-The Agnellis’ risky Philips bet starts to pay off Corrects annotation in graphic in April 29 story to reflect that Exor purchase of Philips shares was announced in August 2023, not August 2021. The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Lisa Jucca MILAN, April 29 (Reuters Breakingviews) - John Elkann’s risky bet on Philips PHG.AS is starting to pay off.
B
P

Bayer Reports Sustained And Clinically Meaningful Benefits In Two Major Retinal Diseases

BRIEF-Bayer Reports Sustained And Clinically Meaningful Benefits In Two Major Retinal Diseases April 29 (Reuters) - Bayer AG BAYGn.DE : EYLEA 8 MG DATA PRESENTATIONS AT ARVO REINFORCE SUSTAINED AND CLINICALLY MEANINGFUL BENEFITS IN TWO MAJOR RETINAL DISEASES Source text for Eikon: [ID:] Further company coverage: BAYGn.DE Reporting by Friederike Hei
B

Agrochemicals company Syngenta posts big drop in Q1 sales, earnings

UPDATE 1-Agrochemicals company Syngenta posts big drop in Q1 sales, earnings Adds details, background ZURICH, April 29 (Reuters) - Seeds and pesticides maker Syngenta suffered big drops in first quarter sales and profit, the company said on Monday, just a few weeks after the Swiss company shelved its plans for a $10 billion flotation. Sales fell 20% to $7.4 billion, Syngenta said, while core operating profit (EBITDA) declined by 34% to $1.2 billion, as farmers continued to run down their supplie
B
B
C

Bayer CEO wins first AGM shareholder vote

Bayer CEO wins first AGM shareholder vote April 26 (Reuters) - Bayer BAYGn.DE CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare and agriculture group, defying a challenge from one German fund managing house. Bayer said investors with 91.69% of the equity capital re
B

Bayer CEO wins first AGM shareholder vote

UPDATE 4-Bayer CEO wins first AGM shareholder vote Releads on vote results By Patricia Weiss and Ludwig Burger FRANKFURT, April 26 (Reuters) - Bayer CEO Bill Anderson on Friday won a vote of confidence at his first annual general meeting (AGM) at the helm of the embattled healthcare and agriculture group, defying a challenge from one German fund managing house.
B
D

Bayer shareholder Deka says it won't endorse management in AGM vote

Bayer shareholder Deka says it won't endorse management in AGM vote FRANKFURT, April 26 (Reuters) - Mutual fund firm Deka Investment, among Bayer's 20 largest shareholders, said it would not give the health care and agriculture company's management a vote of approval at Friday's annual general meeting, citing a lack of focus on the share price. Rep
B

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth April 25 (Reuters) - Regeneron Pharmaceuticals REGN.O and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver.
B
R
V



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques